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Introduction: Various strategies have been explored to decrease the quantity of opioids
prescribed for post-operative pain. The Michigan Opioid Prescribing Engagement Network,
in partnership with BCBS-Michigan, has developed a pain optimization pathway for several
surgical procedures, including prostatectomy. Urologists who follow the pain optimization
pathway, which includes pre-operative patient education and limiting discharge opioids to 6
tablets of oxycodone 5 mg, can report a modifier for additional reimbursement. We explored
the impact of this incentive on inpatient opioid prescribing practices following robotic
assisted radical prostatectomy (RARP).
Methods: Patients undergoing RARP between January 2017 and August 2019 at a single
institution were retrospectively reviewed. This interval included cases both before, and after,
the reimbursement incentive was implemented on July 1, 2018. Outcomes included quantity
of opioid administered during hospitalization, reported in morphine milligram equivalents
(MME), and average inpatient pain scores, reported with numerical pain scale.
Results: A total of 300 patients underwent RARP, 209 prior to implementation of the
reimbursement incentive, and 91 after. Mean MME administered during hospitalization
decreased 18% after the incentive went into effect, from 73 to 54 MME (p=0.04). There was
no difference in average pain scores or length of stay.
Conclusion: For patients undergoing RARP, a reimbursement-based incentive tied
to limiting outpatient opioid prescriptions was associated with a decrease in opioids
administered during hospitalization, with no impact on subjective pain scores or length of
stay. This may reflect the effectiveness of pre-operative patient education on the dangers of
opioid use and alternative pain management options.
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Introduction: Our objective was to evaluate the cost-effectiveness of obtaining preoperative
type and screen (TS) for common urological procedures and to determine patient and
hospital factors associated with receiving blood transfusions.
Methods: Retrospective database analysis of the 2006-2015 Nationwide Inpatient Sample
(NIS) was performed to identify patients undergoing a variety of urological procedures. A
total of 4,113,144 cases were identified. Transfusion rates were then determined from NIS
data, and multivariate regression analyses was used to identify factors associated with
transfusions. A cost-effectiveness analysis was performed to determine the incremental
cost-effectiveness ratio (ICER) of obtaining preoperative TS to prevent an emergencyrelease transfusion (ERT), with a willingness-to-pay threshold of $1,500.
Results: Transfusion rates of common urological procedure ranged from .91% to 33.14%.
On multivariate modeling, all comorbidities with the exception of obesity were significantly
associated with blood transfusion. Some examples included diabetes (OR, 1.26; 95% CI,
1.19-1.33), liver disease (OR, 1.20; 95% CI, 1.13-1.29), and metastatic cancer (OR, 2.69;
95% CI 2.54-2.85) (p < 0.01 for all). One-way sensitivity analysis demonstrated that the risk
of transfusion should exceed 4.12% to justify preoperative TS. The ICER of preoperative TS
for radical prostatectomy (transfusion rate = 3.88%) and penile implants (transfusion rate =
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